Becton Dickinson and (BDX) Updates FY 2019 Earnings Guidance

Becton Dickinson and (NYSE:BDX) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $12.05-12.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.01. The company issued revenue guidance of $17.342B – 17.501 million, compared to the consensus revenue estimate of $15.95 billion.

Shares of Becton Dickinson and stock opened at $237.32 on Tuesday. The stock has a market cap of $63.03 billion, a PE ratio of 25.03, a PEG ratio of 1.40 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and has a twelve month low of $209.91 and a twelve month high of $265.87.

BDX has been the subject of a number of research analyst reports. Morgan Stanley raised their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an equal weight rating in a research report on Thursday, October 4th. KeyCorp restated a buy rating and set a $264.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Citigroup raised their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a buy rating in a research report on Wednesday, August 8th. Barclays initiated coverage on Becton Dickinson and in a research report on Monday, October 15th. They issued an equal weight rating and a $278.00 price target for the company. Finally, Royal Bank of Canada reiterated a hold rating and issued a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Becton Dickinson and presently has an average rating of Buy and a consensus price target of $256.14.

COPYRIGHT VIOLATION WARNING: “Becton Dickinson and (BDX) Updates FY 2019 Earnings Guidance” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/11/06/becton-dickinson-and-bdx-updates-fy-2019-earnings-guidance.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: Short Selling Stocks, A Beginner’s Guide

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply